Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon

Yazhou Li1,5, Kelli L. Vaughan2,3,5, David Tweedie1, Jin Jung4, Hee Kyung Kim4, Ho-Il Choi5, Dong Seok Kim1,4,6, Julie A. Mattison2,6 & Nigel H. Greig1,6*

The time-dependent (30 min - day 84) plasma profile of PT320, a sustained-release (SR)-Exenatide formulation under clinical development for treatment of neurodegenerative disorders, was evaluated in nonhuman primates after a single subcutaneous dose and was compared to Bydureon. Exenatide release from PT320 exhibited a triphasic pharmacokinetic profile. An initial peak occurred at 3 hr post-administration, a secondary peak at 5 days, and achievement of Exenatide steady-state plasma levels from day 10–28. Systemic exposure increased across PT320 doses, and Exenatide levels were maintained above the therapeutic threshold prior to achieving a steady-state. In contrast, Exenatide release from Bydureon exhibited a biphasic profile, with an initial plasma peak at 3 hr, followed by a rapid decline to a sub-therapeutic concentration, and a gradual elevation to provide a steady-state from day 35–49. Exenatide total exposure, evaluated from the area under the time-dependent Exenatide concentration curve, was similar for equivalent doses of PT320 and Bydureon. The former, however, reached and maintained steady-state plasma Exenatide levels more rapidly, without dipping to a sub-therapeutic concentration. Both SR-Exenatide formulations proved well-tolerated and, following a well-regulated initial release burst, generated steady-state plasma levels of Exenatide, but with PT320 producing continuous therapeutic Exenatide levels and more rapidly reaching a steady-state.

The incretin glucagon-like peptide 1 (GLP-1) is a gastrointestinal peptide hormone and proteolytic product of proglucagon. It is predominantly generated within and released by intestinal enteroendocrine L cells to potentiate glucose-dependent insulin secretion by pancreatic β-cells following food ingestion1,2. Further to its well-characterized insulinotropic function and other actions on glucose homeostasis, produced by suppressing glucagon secretion from pancreatic α-cells, slowing gastric emptying and inducing satiety to reduce food intake and body weight, GLP-1 confers glucose sensitivity to glucose-resistant β-cells and provides trophic support by stimulating pancreatic β-cell proliferation and neogenesis, and by reducing β-cell apoptosis3,4. As the glucose homeostasis actions and enhancement of insulin signaling provided by GLP-1 are largely preserved in type 2 diabetes mellitus (T2DM), agents that activate the GLP-1 receptor (GLP-1R), a class B G protein–coupled receptor (GPCR) that mediates the action of GLP-1, a class B G protein–coupled receptor (GPCR) that mediates the action of GLP-1, have been developed for the treatment of T2DM; they appear to be well-tolerated, efficacious and widely used5–9. Furthermore, as the GLP-1R has been found expressed across a wide variety of other organs, such as on neurons within the brain and peripheral nervous system and within all four chambers of the heart, GLP-1R agonists are currently being evaluated across an increasing number of other diseases10–15.

1Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 2SoBran BioSciences, SoBran Inc., Burtonsville, MD, USA. 3Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Dickerson, MD, USA. 4Peptron Inc., Yuseong-gu, Daejeon, Republic of Korea. 5These authors contributed equally: Yazhou Li and Kelli L. Vaughan. 6These authors jointly supervised this work: Dong Seok Kim, Julie A. Mattison and Nigel H. Greig. *email: Greign@mail.nih.gov
GLP-1 has an extremely short half-life (T1/2 1.5 min) within the circulation following either its physiological release or direct administration, with proteolysis, principally by DPP-4 and renal clearance having major roles. DPP-4 cleaves the amino-terminal dipeptide from GLP-1 to reduce its activity1-9,16,17. The identification of this led to the strategies for (i) modifying the peptide to lower proteolysis/renal clearance to generate longer-acting incretin mimetics and (ii) to elevate endogenous GLP-1 levels by using DPP-4 inhibitors. In relation to the former, an increasing number of GLP-1R agonists have been developed for clinical use and, as trials and experience with them grow, it will become clearer whether one has advantages over another within specific clinical settings. A practical way to categorize clinically available GLP-1R agonists is based on their duration of action. Centered on their pharmacokinetic/ pharmacodynamic profile, they can be divided into short-acting (Exenatide (Byetta): T1/2 2.4 hr18, and lixisenatide T1/2 3 hr19: administered twice and once daily, respectively) and long-acting GLP-1R agonists (Exenatide long-acting release (LAR (Bydureon)), lixisenatide T1/2 13 hr, albiglutide T1/2 6–7 days, and dulaglutide T1/2 4 days20,21: administered from once daily to weekly (Supplemental Table 1)). A key distinction between short- and long-acting GLP-1R agonists is that, when administered in line with their approved dosing schedule, the former group is subject to wide fluctuations in the plasma concentration of active compound, whereas the latter provides a more stable and sustained GLP-1R activation20,21.

Exenatide was the first approved GLP-1R agonist for T2DM as a twice daily medication (Byetta: 2005) and its extended release formulation, Exenatide as Bydureon, was approved in 2012 for once weekly dosing. Both are well-tolerated and remain widely used1-9,21. In contrast to lixisenatide that reversibly binds to serum albumin, albiglutide that is the fusion product of two modified GLP-1 molecules with albumin, and dulaglutide that comes from a de novo designed molecule, Exenatide is formulated into PLGA can transform the release kinetics and the resulting pharmacokinetics of the drug23–26.

### Results
Exenatide administration in the form of both PT320 (0.44 and 1.1 mg/kg) and Bydureon (1.1 mg/kg) proved to be well-tolerated at the doses evaluated, albeit hard nodules (in general 2 × 2 cm in size) were evident within the subcutaneous injection site across groups (3 of 4: PT320 0.44 mg/kg; 4 of 4: PT320 1.1 mg/kg; 4 of 4: Bydureon 1.1 mg/kg). For one animal in the PT320 1.1 mg/kg group (Monkey #12), the nodule broke the skin surface and...

|                     | PT320 0.44 mg/kg (A) | PT320 1.1 mg/kg (B) | Bydureon 1.1 mg/kg (C) |
|---------------------|----------------------|---------------------|------------------------|
| C_max (pg/ml)       | 924.5 ± 62.9 (R,C)   | 1740.2 ± 86.1 (A)   | 1960 ± 167.8 (A)       |
| T_max (hr)          | 1.75 ± 0.7           | 3                   | 3                      |
| C_trough (pg/ml)    | 72.1 ± 10.9 (R,C)    | 137.7 ± 21.7 (A,C)  | 8.6 ± 3.2 (A,B)        |
| T_lag (hr)          | 60 ± 12              | 72                  | 24                     |
| C_trough (pg/ml)    | 1227.9 ± 251.3       | 1535.7 ± 167.7      | 1617.4 ± 272.5         |
| T_max (hr)          | 438 ± 66 (18.25 days) (C) | 416 ± 88 (17.3 days) (C) | 966 ± 80.4 (40.25 days) (A,B) |
| Approx. steady-state| Day 10–28            | Day 10–28           | Day 35–49              |
| C_max (pg/ml)       | 586.4 ± 0.35 (C)     | 676.9 ± 0.49 (B)    | 658.7 ± 0.56 (C)       |
| AUC: 0–24 hr        | 12,540.2 ± 1,229.2 (B) | 19,990.0 ± 839.1 (A) | 18,375.1 ± 2,712.6     |
| AUC: 0–2016 hr (i.e., day 0–84) | 490,291.4 ± 113,343.2 (C) | 738,234.0 ± 109,532.3 | 848,585.2 ± 91,142.9 (A) |
| AUC: 240–672 hr (i.e., day 10–28) | 350,090.2 ± 81,035.8 | 451,360.0 ± 111,800.4 (C) | 182,033.8 ± 28383.2 (B) |
| AUC: 840–1176 hr (i.e., day 35–49) | 10,486 ± 5,949 (C)   | 71,914 ± 34,376 (C) | 373,149 ± 44,892 (A,B) |

Table 1. Pharmacokinetic parameters of Exenatide following a single subcutaneous administration of PT320 (0.4 and 1.1 mg/kg) and Bydureon (1.1 mg/kg) to nonhuman primates. C: Bydureon 1.1 mg/kg group is significantly different from the control group (p ≤ 0.05). B: PT320 1.1 mg/kg group is significantly different from the comparison group (p ≤ 0.05). A: PT320 0.44 mg/kg group is significantly different from the comparison group (p ≤ 0.05). C_max: Initial peak plasma concentration associated with the initial release burst of Exenatide. T_max: Time of C_max. T_lag: Time of C_trough. T_max - T_lag: Average plasma concentration of Exenatide (calculated from time zero up to the time when plasma levels were greater than 50 pg/ml (considered the minimal therapeutic concentration28). AUC: are under the Exenatide plasma concentration curve between the defined times.
resulted in drug loss (occurring at approximately weeks 3 and 4), and hence this animal was removed from the pharmacokinetic analysis. The mean body weight of rhesus monkeys is shown in Fig. 1, which decreased across all groups, reaching a trough between weeks 4 to 6 (day 28 to 42), and recovering nearly to baseline levels by week 12 (day 84).

An initial release burst of Exenatide was evident in plasma as early as 30 min after administration of either dose of PT320 or of Bydureon. Illustrated in Fig. 2A is a semi-log plot of plasma Exenatide (pg/ml) levels versus time (hr) that combines animals within each of the three groups (PT320 0.44 and 1.1 mg/kg, and Bydureon 1.1 mg/kg). Following this initial Exenatide release, plasma levels declined across all treatment groups by 24 hr, reaching a trough (C_{trough}) between 60 and 72 hr. For animals administered either dose of PT320, a secondary peak was consistently evident at 5 days, and approximately steady-state Exenatide plasma levels were then achieved from days 10 to 28 post administration (i.e., from approx. 1.5 to 4 weeks). In contrast, following Bydureon administration, plasma levels of Exenatide gradually and time-dependently increased to achieve an approximate steady-state concentration between day 35 to 49 (5 to 7 weeks) post injection; rapidly declining at week 8 and being minimal thereafter.

Figure 3 demonstrates linear time-dependent curves of Exenatide levels in plasma for each nonhuman primate, which allows an appreciation of the variance between individual animals administered either dose of PT320 or Bydureon. Such variance is not uncommon in nonhuman primates as, phylogenetically close to humans, they possess substantial outbred genetic variability, as compared to rodents32,33. Notably, and shown in Table 1, is that the plasma Exenatide concentration and time associated with the initial release burst, C_{peak} and T_{peak}, following subcutaneous administration is remarkably similar between the matched 1.1 mg/kg doses of PT320 (1740.2 ± 86.1 pg/ml at 3 hr) and Bydureon (1960 ± 167.8 pg/ml at 3 hr) (p = 0.35). Likewise, the maximal concentrations, C_{max}, achieved by these different formulations are also comparable; 1535.6 ± 167.7 and 1617.4 ± 272.5 pg/ml (p = 0.83), respectively. However, the time to achieve these, T_{max}, was significantly shorter for PT320 compared to Bydureon (416 ± 88 h (i.e., 17.3 days) vs. 966 ± 80.4 h (i.e., 40.25 days), p = 0.006), and is reflected in the different time-dependent AUC values (Table 1 and Fig. 2B).

A notable difference between Exenatide administered as PT320 or as Bydureon is the depth of the decline in plasma levels of Exenatide that followed the initial release burst. Whereas the time-dependence of the decline was similar across formulations, reaching a trough between 24 and 72 hr (T_{trough}), the lowermost Exenatide plasma concentration (C_{trough}) maintained by Bydureon was significantly less (8.6 ± 3.2 pg/ml at 24 hr) than that achieved by PT320 (0.44 mg dose: 72.1 ± 10.9 pg/ml at 60 hr; 1.1 mg dose: 137.7 ± 21.7 pg/ml at 72 hr) (Table 1). Also, of note is the similarity in the shape of the time-dependent Exenatide concentration curves generated by the two evaluated doses of PT320 (0.44 and 1.1 mg/kg) in nonhuman primates (Figs. 2 and 3). Whereas the times associated with the Exenatide initial release burst, subsequent trough and maximal concentration, T_{peak}, T_{trough} and T_{max}, were similar for the PT320 0.44 and 1.1 mg/kg doses (specifically, T_{peak}: 1.75 ± 0.7 vs. 3.0 ± 0.0 hr (p = 0.2), T_{trough}: 60 ± 12 hr vs. 72 ± 0.0 hr (p = 0.4); T_{max}: 438 ± 66 hr (18.25 days) vs. 416 ± 88 hr (17.3 days) (p = 0.85), respectively), the concentrations associated with these demonstrated dose-dependence (C_{peak}: 924.5 ± 62.9 vs. 1740.2 ± 86.1 pg/ml (p = 0.0055); C_{trough}: 72.1 ± 10.9 vs. 137.7 ± 21.7 pg/ml (p = 0.03); C_{max}: 1227.7 ± 251.3 vs. 1535.6 ± 167.7 pg/ml (p = 0.39), respectively).
As the development of anti-Exenatide antibodies is not uncommon in human clinical studies due to a low homology of Exenatide to native GLP-1, we evaluated the development of such antibodies by Sandwich ELISA across all animals from plasma samples obtained at 6 and 12 weeks post PT320 or Bydurion administration. As illustrated in Table 2, two of 12 animals developed a positive titer that was present at both times (specifically, nonhuman primates #4 and #12).

Discussion

The goal of the current study was to evaluate the pharmacokinetic properties of a single-dose of PT320 in healthy nonhuman primates. PT320 is a form of PT302 that is being developed for neurological disorders. Specifically, we characterized the time-dependent levels of plasma Exenatide following two single doses of PT320 (1.1 and 0.44 mg/kg) to provide an initial evaluation of dose-dependence. Additionally, we compared the higher PT320 dose to a matched single dose of Bydureon (1.1 mg/kg) to evaluate the equivalences of these two different SR Exenatide formulations. Systemic Exenatide exposure was measured periodically for 84 days (2016 hr) following a single subcutaneous dose of these formulations. These doses were based on a prior Bydureon study in nonhuman primates (Cynomolgus monkeys) in which single doses of 0.11, 0.44 and 1.1 mg/kg were evaluated from 0.5 hr to 71 days, and proved to be well-tolerated. The minimally effective concentration of Exenatide in humans has been reported as approximately 50 pg/ml, as this is the level required to reduce fasting plasma glucose levels. In using 50 pg/ml as a ‘cutoff limit,’ the PT320 0.44 mg/kg administration provided a therapeutic level of dosing for up to 31.5 days (756 ± 84 hr), the PT320 1.1 mg/kg dose for up to 44 days (1064 ± 112 hr), and the Bydureon 1.1 mg/kg dose for 52 days (1260 ± 48.5 hr) in nonhuman primates (with no significant difference in this duration between the 1.1 mg PT320 and Bydureon formulations; p = 0.13). These results are in accord with data from human studies evaluating the pharmacokinetics of Exenatide release from PT302 in which concentration-dependent release was measured for up to 55 days following a single subcutaneous dose of PT302, and for some 60 days (8.5 weeks) following Bydureon, and, additionally, are consistent with weekly to biweekly dosing.

In the clinical setting for the treatment of T2DM, as well as for other disorders, Exenatide is routinely administered chronically; over months to years duration. This would involve once weekly dosing of Bydureon and either once weekly or once every other week dosing for PT320. Albeit not the focus of our single dose study, such multiple dosing would be expected to impact plasma Exenatide levels achieved at 7 and 14 days onwards, after Bydureon and PT320, respectively, and to maintain steady-state levels over a far longer duration. Importantly, Exenatide plasma levels associated with multiple dosing of either Bydureon or PT320 would be...
Figure 3. Linear time-dependent plasma Exenatide concentration plots for individual nonhuman primates administered a single subcutaneous dose of (A) PT320 (0.44 mg/kg), (B) PT320 (1.1 mg/kg) and (C) Bydureon (1.1 mg/kg). *Non human primates #4 and #12 demonstrated anti-Exenatide antibodies at 6 and 12 week evaluation times. Nonhuman primate #12 was excluded from analysis of pharmacokinetic parameters as drug loss occurred at the skin surface at approximately week 3 to 4 (504 to 672 hr).

Table 2. Anti-Exenatide antibodies evaluated in plasma at 6 and 12 weeks post subcutaneous Exenatide administration in the form of either PT320 (0.44 or 1.1 mg/kg) or Bydureon (1.1 mg/kg) to nonhuman primates. (+): positive antibody titer; (−): no antibody titer.
similar to that achieved with a single dose prior to 7 and 14 days, respectively, as only a single dose would have been administered at these times.

A consistent initial peak in plasma Exenatide was noted following PT320 administration to nonhuman primates within 1.75 to 3 hr, which is comparable to the characteristic peak seen in humans that occurs within 4 hr of dosing⁴⁸. This first phase is caused by the ‘burst release’ of Exenatide occurring from the PLGA nanospheres in which the drug is encapsulated. This predominantly derives from Exenatide on or close to the surface that enters the systemic circulation on initial nanosphere hydration prior to the onset of polymer erosion-associated Exenatide release²⁵,³⁹. An initial peak in plasma Exenatide was likewise evident following Bydureon administration to nonhuman primates at 3 hr, in line with human studies in which a peak at 2.1 to 5.1 hr was noted⁵⁷. Our study indicates that the concentration of the initial burst release in nonhuman primates appeared to be well-regulated across both Exenatide SR formulations, and was dose-dependent, with the C_max value approaching that of the C_max value (PT320 0.44 and 1.1 mg/kg 75% and 113%, and Bydureon 1.1 mg/kg 121%); and the variance around the C_max value is relatively small (6.8%, 4.9% and 8.6%, respectively re: SEM as a percent of the mean value). This initial burst peak was relatively short in duration, with Exenatide plasma concentrations declining rapidly by 24 hr to provide a time-dependent concentration of less than 3% of the total exposure to Exenatide (AUC_0-24 hr ÷ AUC_0-2016 hr). This is in accord with studies of PT320 in humans in which the value of C_max was likewise comparable to C_max and the initial Exenatide burst represented only a small fraction of the total drug exposure (1.2% to 3.8% over the initial 12 hr⁶⁰). Controlling the initial release of a drug from a SR preparation is a key parameter in the development of an extended release drug delivery system to rapidly achieve a therapeutic concentration without inducing an unregulated spike in drug level to potentially provoke an adverse action²⁴,²⁵,³⁹, such as nausea or vomiting, which are not uncommon following the initial use of immediate release Exenatide (Byetta)⁴⁵,⁴⁸,²¹,²².

Also evident from our time-dependent analysis of plasma Exenatide concentrations generated by PT320 or Bydureon in nonhuman primates (Fig. 2A) is the short ‘lag phase’ (i.e., the decline in drug levels released into plasma) following the initial burst peak prior to the generation of relatively stable Exenatide levels. A key difference between the matched 1.1 mg PT320 and Bydureon doses was the depth of the decline in plasma Exenatide; falling to a sub-therapeutic concentration for Bydureon (C_Itrough: 8.6 ± 3.2 pg/ml) at 24 hr across all (4/4) nonhuman primates and persisting at a sub-therapeutic level in 3/4 animals at 72 hr (Fig. 3C). In contrast, plasma Exenatide levels declined to a C_Itrough of 137.7 ± 21.7 pg/ml in 1.1 mg PT320 animals, with none from either PT320 doses declining below a therapeutic level (50 pg/ml⁶⁰).

A secondary peak in plasma Exenatide levels was evident at 5 days following either dose of PT320 and, after a further decline of short duration, Exenatide levels reached and maintained a relatively steady-state concentration from days 10 to 28. The difference between the C_Ave and C_max values was in the order of 2-fold (from Table 1; PT320 0.44, PT320 1.1 and Bydureon 1.1 mg/kg: 2.1-, 2.3- and 2.5-fold, respectively). A smaller disparity between C_Ave and C_max for a drug delivery system is associated with superior extended release while concurrently maintaining the peptide in a stable form in vivo²³,²⁴.

A further major difference between Exenatide released from PT320 and Bydureon administration was related to the time required to reach steady-state plasma levels in nonhuman primates. For both PT320 doses this was achieved within 10 days and lasted up to day 28 (10 days duration), with plasma Exenatide levels never falling below the minimal therapeutic concentration of 50 pg/ml⁶⁰ prior to achieving the steady-state. In contrast, Bydureon achieved steady-state levels of plasma Exenatide from approximately day 35 to 49 (14 days duration). Bydureon briefly declined to sub-therapeutic levels following the initial burst phase, and then gradually increased over time (Fig. 3C). Notable is the equivalence of the concentrations of Exenatide achieved for the matched 1.1 mg/kg doses of PT320 and Bydureon, whether the C_peak, C_max or C_Ave values, which were remarkably similar (Table 1)⁴⁸. As noted, the time (T_max) to achieve the C_max was shorter for PT320 (48 hr), which is reflected in the AUC values (Table 1 and Fig. 2B). Also evident is that the C_peak, C_Ave and C_max values demonstrate dose-dependence for both the PT320 0.44 and 1.1 mg/kg administrations, with the maintenance of the times to achieve these (Table 1). In comparison, in human subjects with T2DM administered PT320 the Exenatide C_max occurred between 23 and 27 days, and demonstrated dose-dependence⁴⁸. For Bydureon in humans with T2DM, the C_max occurred between 39 to 48 days following administration and, likewise, was dose dependent⁵⁷.

Following the initial burst release phase of Exenatide from the PLGA microsphere surface of either PT320 or Bydureon, the microspheres hydrate, adhere to one another, and create an in situ matrix drug reservoir. Continuous diffusion from this matrix results in the secondary release phase of Exenatide into plasma that, followed by the hydrolysis and erosion of the PLGA polymer, results in the steady-state Exenatide third release stage²³,²⁵,³⁹. The PLGA polymer hydrolysis products, lactic and glycolic acids, are ultimately eliminated as carbon dioxide and water²³. Whereas PLGA is a biodegradable and biocompatible medical polymer with a well-established safety profile as an excipient in a wide variety of controlled release drugs²³,²⁵,³⁹, the appearance of subcutaneous injection site reactions for Bydureon is reported to be 17.1% from clinical data presented within the US approved prescribing information⁴¹. When present, these reactions may occur after the first dose (70%), and cause local skin discoloration (70%), pain or discomfort (56%), pruritus (48%), warmth (33%), and swelling (30%) at the injection site. Most cases reported nodules characterized as hard, subcutaneous, lumps, masses, or inductions⁴¹, with a minority (22%) of cases reporting a concurrent abscess. The occurrence of injection site induration and pruritus was also noted in T2DM subjects administered Exenatide, and is described to be dose-dependent and to naturally resolve⁴⁰. In our nonhuman primate study, such Bydureon and PT320 associated nodules were evident across all animals (12 of 12) with one demonstrating an abscess (1 of 12), and all self-resolved. In contrast, Bydureon in humans is routinely administered as a dose of 2 mg in a 0.65 ml injection volume (or 0.85 ml for Bydureon BCISE)²², and hence the doses and corresponding injection volumes are substantially larger in our nonhuman primate study (mean values: 1.7 and 4.1 ml for PT320 0.4 and 1.1 mg/kg doses,
and 3.5 ml for Bydureon 1.1 mg/kg dose), and likely resulted in a higher injection reaction site incidence and unusual loss of drug in nonhuman primate #12.

Our study was specifically designed to follow time-dependent Exenatide levels achieved by the sustained release formulations PT320 and Bydureon, rather than to evaluate the Exenatide elimination half-life from plasma – which is generally unchanged when the same drug entity is administered either by immediate or sustained release preparation42,43. Notable across both PT320 doses and Bydureon administration in our nonhuman primate study is the rapid decline in plasma Exenatide levels at the end of steady-state, coinciding with the exhaustion of the drug reservoir. This is in accord with a prior pharmacokinetic study of subcutaneous immediate release Exenatide in rhesus monkeys in which the terminal disappearance half-life from plasma ranged from 0.78 to 1.94 hr.44. Studies across animal species and humans indicate that Exenatide, whether administered by immediate or sustained release, is predominately eliminated by the kidney via glomerular filtration with subsequent enzymatic degradation45. Studies in nephrectomized rats demonstrated that Exenatide slowly disappeared from plasma signifying the occurrence of a non-renal clearance component46. This may involve target-mediated drug disposition47, encompassing the binding of Exenatide to the GLP-1R, and the formation of Exenatide-GLP-1R complexes that either dissociate or become internalized and targeted for receptor-mediated endocytosis and degradation48.

In the light of reports of anti-Exenatide antibody development in human studies focused on Exenatide use in T2DM1–3,34,35 as well as in preclinical studies31, we evaluated whether such an occurrence transpired in our nonhuman primate study by evaluating plasma samples at 6 and 12 weeks. Two of 12 animals (16.7%) demonstrated a positive antibody titer. Interestingly, these two (nonhuman primates #4 and #12 in the PT320 0.44 and 1.1 mg/kg groups, respectively) were associated with lower values of plasma Exenatide (Fig. 3). Bydureon was reported to induce anti-exenatide antibodies as early as day 29 at ≥0.44 mg/kg dose in nonhuman primate studies undertaken by the original manufacturer [35 (page 57)], in a 3 month study involving once weekly administration. Low anti-Exenatide antibody titers (≤125) have been reported in 32% and 45% of T2DM patients administered Exenatide either as BID Byetta or as once weekly Bydureon, respectively, within 24 to 30 weeks of treatment, and are considered to not impact efficacy34,37. Higher-titer antibodies (≥625) less commonly occur (5% and 12% of patients, respectively) and may diminish Exenatide efficacy37. Such antibodies do not appear to cross-react with human GLP-1 or glucagon, or influence the safety profile of Exenatide formulations37.

In summary, our evaluation of a matched dose of the SR-Exenatide formulations PT320 and Bydureon (1.1 mg/kg) in nonhuman primates demonstrated a similar, well-regulated, initial burst release of Exenatide into plasma within 3 hr. This was followed by a lag phase and a secondary and tertiary release stage of Exenatide to provide reasonably steady-state levels in plasma. Whereas the plasma levels of Exenatide associated with Cpeak, CMax, and CAve were equivalent, importantly the time to achieve CMax (TMax) and the steady-state occurred significantly earlier for PT320. Furthermore, the dramatic decline in plasma Exenatide levels that followed the Cpeak and resulted in the Ctrough was attenuated in the PT320 formulation and, unlike Bydureon, continuously maintained therapeutic drug levels prior to reaching steady-state delivery. Evaluation of a lower PT320 dose (0.44 mg/kg) in nonhuman primates demonstrated dose-dependence in relation to Cpeak, Ctrough, CMax and CAave values, with maintenance of the times to achieve these and the duration of the steady-state. Notably, our CMax and AUC (0–2160 hr) values for Bydureon 1.1 mg/kg are in accord with prior preclinical nonhuman primate data that supported the agent’s approval for clinical use (see: CMax and AUC (0–1704 hr) in35). For treatment of disorders involving the use of an SR-Exenatide formulation in which the rapid generation and long-term maintenance of therapeutic plasma and target levels is desired, as could be considered in the experimental treatment of mild and moderate head injury29,30,31 or acute ischemic injury34–37 (see for example clinical trials: NCT03287076 and NCT02829502), the pharmacokinetic characteristics of Bydureon may prove particularly important; associated with the rapid achievement and maintenance of therapeutic Exenatide levels in plasma. For chronic disorders, such as T2DM and PD in which Exenatide has demonstrated value1–3,5–11,13,14,20–22,58, both sustained release formulations would appear to be valuable to achieve and maintain long-term steady-state drug levels through the dosing of Bydureon once weekly and PT320 either once every two weeks or once weekly.

**Materials and Methods**

**Study subjects.** Nonhuman primates were used in this study to provide a closer translational link in relation to evaluating a new drug formulation destined for use in humans, as compared to studies in rats30,35. Animals included 12 male (4–11 years old) rhesus macaques (Macaca mulatta) randomized into three treatment groups (n = 4). Monkeys were maintained at the National Institutes of Health Animal Center (Poolesville, MD) and housed in standard primate caging with a controlled temperature and humidity and a 12-hr light cycle. Commercially prepared monkey chow was distributed twice per day along with daily food enrichment, and water was available ad libitum. Monkeys were observed daily for food consumption and overall well-being. Animal husbandry and all experimental procedures complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were conducted under approved protocols by the National Institute on Aging Intramural Research Program Animal Care and Use Committee.

**Experimental design.** At each procedure, monkeys were restrained with ketamine (3–5 mg/kg, IM), which was supplemented with partial doses of ketamine, as needed, to maintain anesthesia. Following an initial baseline blood draw to obtain background signal levels for Exenatide ELISA evaluations, one of three pharmacological grade treatments was administered subcutaneously into the abdomen (with the selected doses representing the active pharmaceutical ingredient (API) within each Exentatide sustained release formulation – to ensure matching of the Exenatide in PT320 and Bydureon (this was undertaken to account for the different percents of API, approx. 2% and 5%, respectively, within these formulations). The treatment groups included (i) PT320 0.44 mg/kg (mean body weight 10.45 ± 1.18 kg; injection volume 160 ul/kg), (ii) PT320 1.1 mg/kg (mean body weight
following plasma removal, separate aliquots were frozen and stored at 80 °C. This value was then subtracted from time-dependent values in the same animal. The pharmacokinetic parameters which were analyzed with noncompartmental methods using WinNonlin (version 6.0; Pharsight Corporation, Cary, NC). The baseline (zero time) sample was quantified for each animal as a level of ‘background signal’, and which were assessed by following Exenatide time-concentration profiles and pharmacokinetic parameters, (CMax), and time to reach it (TMax). (iv) The lag time between the achievement of CIpeak and CMax (TLag). (v) The area under the curve from 0 to the last time point (AUC0–last), as calculated by the linear trapezoidal and log-linear truncated peptide that is a major endogenous metabolite in vivo yields an N-terminally glycosylated peptide with a molecular weight of 5670 Da.

Anti-Exenatide antibody measurement. As both PT320 and Bydureon are slow-release formulations of Exenatide and our study extended over a period of 12 weeks, we evaluated plasma anti-Exenatide antibody levels at both week 6 and week 12 using a previously developed homemade Sandwich ELISA. In brief, ELISA plates were coated with Exenadine-4 (concentration: 2 μg/ml in coating buffer) at 4 °C overnight, and following blocking and washing steps, standards (mouse monoclonal anti-Exenatide antibody) and unknown samples with serial dilutions were added to the plate and incubated at room temperature for 1 h. After washing, biotynlated-Exenatide (concentration: 2 μg/ml) was added, and was followed by washing and SA-HRP detection. The titers of the anti-Exenatide antibody within the samples were then estimated by serial dilution of the plasma (to a maximum dilution of 1:225). We used results from the 1:25 dilution of all samples to determine whether a positive or negative development of anti-Exenatide antibodies had occurred across all 12 nonhuman primates evaluated in our study.

Statistics and pharmacokinetic evaluation. The pharmacokineti characteristics of PT320 and Bydureon were assessed by following Exenatide time-concentration profiles and pharmacokinetic parameters, which were analyzed with noncompartmental methods using WinNonlin (version 6.0; Pharsight Corporation, Cary, NC). The baseline (zero time) sample was quantified for each animal as a level of ‘background signal’, and this value was then subtracted from time-dependent values in the same animal. The pharmacokinetic parameters evaluated included (i) the initial peak concentration (Cpeak) associated with the initial release burst of Exenatide, and the time to reach Cpeak (Tpeak). (ii) The lowest concentration of Exenatide in plasma (Ctrough) achieved subsequent to the Cpeak, and the time of this decline (Ttrough). (iii) The ultimate maximal Exenatide concentration (Cmax), and time to reach it (Tmax). (iv) The area under the curve from 0 to the last time point (AUC0–last), as calculated by the linear trapezoidal and log-linear trapezoidal methods. The lower limit of quantitation (LLOQ) for Exenatide in our study was 3.1 pg/ml.

Data availability
The dataset analyzed during the current study is available from the corresponding author on reasonable request.

Received: 22 July 2019; Accepted: 22 October 2019;
Published online: 20 November 2019

References
1. Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819–37 (2013).
2. Tolhurst, G., Reimann, F. & Gribble, F. M. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 587, 27–32 (2009).
3. Chon, S. & Gautier, J. F. An Update on the effect of incretin-based therapies on β-cell function and mass. Diabetes Metab. J. 40, 99–114 (2016).
4. Koehler, J. A. et al. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 64, 1046–1056 (2015).
5. Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).
6. Nauck, M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obes. Metab. 18, 203–216 (2016).
7. McBrayer, D. N. & Tal-Gan, Y. Recent advances in GLP-1 receptor agonists for use in diabetes mellitus. Drug Dev Res. 78, 292–299 (2017).
8. Knoop, P. K., Bronden, A. & Vilsbo, T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother. 18, 555–571 (2017).
9. Sfairopoulos, D., Liatis, S., Tigas, S. & Liberopoulos, E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens) 17, 333–350 (2018).
10. Boyle, J. G., Livingstone, R. & Petrie, J. R. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Clin Sci (Lond). 132, 1699–1709 (2018).
11. Gallego-Colon, E., Wojakowski, W. & Francuz, T. Incretin drugs as modulators of atherosclerosis. Atherosclerosis. 278, 29–38 (2018).
12. Tomlinson, B., Hu, M., Zhang, Y., Chan, P. & Liu, Z. M. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs 25, 1167–179 (2016).
13. Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664–1675 (2017).
14. Kim, D. S. et al. A new treatment strategy for Parkinson’s disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant. 26, 1560–1571 (2017).
15. Glatofeltt, E. J. et al. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. ACS Pharmacol. Transl. Sci. 2, 66–91 (2019).
16. Deacon, C. F., Johnsen, A. H. & Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally trun-cated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80, 952–957 (1995).
17. Oshima, I., Hirota, M., Ohboshi, C. & Shima, K. Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats. *Regulatory Peptides* **21**, 85–93 (1998).
18. Bray, G. M. Exenatide. *Am J Health Syst Pharm.* **63**, 411–418 (2006).
19. Bain, S. C. The clinical development program of lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist. *Diabetes Ther.* **5**, 367–383 (2014).
20. Evans, M., Bain, S. C. & Vora, J. A systematic review of the safety of incretin-based therapies in type 2 diabetes. *Expert Rev Endocrinol Metab.* **11**, 217–232 (2016).
21. Gentillella, R., Pechtnier, V., Corcos, A. & Consoli, A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev.* **35**(1), e3070 (2019).
22. Yu, M. et al. Battle of GLP-1 delivery technologies. *Adv Drug Deliv Rev* **130**, 113–130 (2018).
23. DeYoung, M. B., MacConell, L., Sarin, V., Trautmann, M. & Herbert, P. Encapsulation of exenatide in poly(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. *Diabetes Technol. Ther.* **13**, 1145–54 (2011).
24. Lewis, A. & Kumar, R., Bydureon Development at Alkermes: Interview with Rajesh Kumar [WWW Document], https://www.controlledreleasesociety.org/publications/intrack/Pages/it0002.aspx (accessed 11.08.18) (2012).
25. Schwendeman, S. P., Shah, R. B., Bailey, B. A. & Schwendeman, A. S. Injectable controlled release depots for large molecules. *J Control Release* **190**, 240–53 (2014).
26. Ruan, S. et al. Long-acting release microspheres containing novel GLP-1 analog as an anti-diabetic system. *Mol Pharm.* **15**, 2857–2869 (2018).
27. Peptron Inc., Daejeon, 34054, Republic of Korea. On-going phase II study of PT320, a long-acting Exenatide, the First-In-Class Drug for Parkinson’s Disease Therapy: http://www.pepton.com/ds2_2_1.html (link accessed 10.11.2019).
28. Chen, S. et al. Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease. *Sci Rep.* **8**, 10722 (2018).
29. Bader, M. et al. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. *Neurobiol Dis.* **124**, 439–453 (2019).
30. Gu, N. et al. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. *Clin Ther.* **36**, 101–114 (2014).
31. Peptron Inc., Daejeon, 34054, Republic of Korea. SmartDepot™ technology. http://pepton.com/ds2_2_1.html (accessed 10.11.2019).
32. Vallender, E. J. & Miller, G. M. Nonhuman primate models in the genomic era: a paradigm shift. *ILAR J.* **54**, 154–65 (2013).
33. SCHEER (Scientific Committee on Health, Environmental and Emerging Risks), Final Opinion on ‘The need for non-human primates in biomedical research, production and testing of products and devices (update 2017)’ 18 May 2017. https://ec.europa.eu/environment/chemicals/lab_animals/pdf/Scheer_may2017.pdf (accessed 10.11.2019).
34. Peng, H., Want, L. L. & Aroda, V. R. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. *Curr Diab Rep* **16**, 44 (2016).
35. Exenatide LAR (AC2993-F17): Pharmacokinetics and Immunogenicity following Single-Dose Subcutaneous Administration in the Cynomolgus Monkey (Report REST041K82R1). In, Center for Drug Evaluation and Research Application Number: 022200Orig15000; Pharmacology Review, pages 87-88 (2009). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig15000PharmR.pdf (accessed 10.11.2019).
36. Taylor, K. et al. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. *Horm Metab Res.* **37**, 627–32 (2005).
37. Feneian, M. et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. *Clin Pharmacokinet.* **50**, 65–74 (2011).
38. Kanwar, N. & Sinha, V. R. *In situ* forming depot as sustained-release drug delivery systems. *Crit Rev Ther Drug Carrier Syst.* **36**(2), 93–136 (2019).
39. Wang, J., Wang, B. M. & Schwendeman, S. P. Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. *J Control Release* **82**, 289–307 (2002).
40. Fan, F. & Yang, M. Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. *Int J Pharm.* **498**, 82–95 (2016).
41. Jones, S. C., Ryan, D. L., Pratt, V. S. W., Niak, A. & Brinker, A. D. Injection-site nodules associated with the use of Exenatide extended-release reported to the U.S. Food and Drug Administration Adverse Event Reporting System. *Diabetes Spectr* **28**, 283–288 (2015).
42. Gidal, B. E., Clark, A. M., Anders, B. & Gilliam, F. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. *Epilepsy Res.* **129**, 26–32 (2017).
43. Whelam, J. W. & Phelps, S. J. A clinician’s guide to oral extended-release drug delivery systems in epilepsy. *J Pediatr Pharmacol Ther.* **23**, 277–292 (2018).
44. Ai, G. et al. Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. *Int J Pharm.* **353**(1-2), 56–64 (2008).
45. Copley, K. et al. Investigation of exenatide elimination and its *in vivo* and *in vitro* degradation. *Curr Drug Metab* **7**, 367–374 (2006).
46. Parkes, D. et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. *Drug Dev Res* **53**, 260–267 (2001).
47. Magee, D. E. & Jusko, W. J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. *J Pharmacokin Pharmacodyn.* **28**, 507–532 (2001).
48. Gao, W. & Jusko, W. J. Target-mediated drug disposition and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. *Drug Metab Dispos.* **49**, 990–997 (2012).
49. Neigh, N. H. et al. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. *Alzheimers Dement.* **10**(1 Suppl), S62–75 (2014).
50. Tweedie, D. et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. *Exp Neurol.* **239**, 170–182 (2013).
51. Eakin, K. et al. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. *PLoS One.* **8**(12), e82016 (2013).
52. Tweedie, D. et al. Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. *Alzheimers Dement.* **12**, 34–48 (2016).
53. Rachmany, L. et al. Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in *vivo* TBI-induced hippocampal cellular degeneration. *Sci Rep.* **7**, 3735 (2017).
54. Li, Y. et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. *Proct Nalt Acad Sci USA* **106**, 1285–1290 (2009).
55. Brijal, S., Gulati, K. & Gulati, A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. *Brain Res.* **1427**, 23–34 (2012).
56. Woc, J. S. et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. *Arterioscler Thromb Vasc Biol.* **33**, 2252–2260 (2013).
57. Muller, C. et al. Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia. *Int J Stroke.* 13, 857–862 (2018).

58. Athauda, D. et al. What effects might exenatide have on non-motor symptoms in Parkinson’s disease: a post hoc analysis. *J Parkinsons Dis.* 8, 247–258 (2018).

Acknowledgements
This research was supported in part by (i) the Technological Innovation R&D Program (S2174574) funded by the Small and Medium Business Administration (Republic of Korea); (ii) Peptron Inc., Daejeon, Republic of Korea; (iii) the Bio and Medical Technology Development Program (NRF-2014M3A9B5073868) of the National Research Foundation (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP) of Korea, and (iv) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, USA.

Author contributions
D.S.K., H.K.K., H.I.C., J.A.M., N.H.G. designed studies; H.I.C., H.K.K., J.J., D.S.K. synthesized, undertook preliminary studies and provided PT320; K.L.V., J.A.M. undertook nonhuman primate studies; Y.L., D.T. undertook assays; D.S.K., Y.L., D.T., H.K.K., J.J., H.I.C., N.H.G. analyzed data; N.H.G., D.S.K., V.L.K., J.A.M., J.J., H.K.K., H.I.C., Y.L., D.T. wrote the manuscript.

Competing interests
J., H.K.K., D.S.K. and H.J.I.C. are employees of Peptron Inc. The Intramural Research Program of the National Institute on Aging, N.I.H., and Peptron Inc. have a Cooperative Research and Development Agreement to develop Exenatide as a treatment strategy for neurodegenerative disorders for which NIA and Peptron Inc. hold patent rights via the work of H.K.K., D.S.K., H.I.C. and N.H.G.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-53356-2.

Correspondence and requests for materials should be addressed to N.H.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019